Clopidogrel/omeprazole - Cogentus Pharmaceuticals

Drug Profile

Clopidogrel/omeprazole - Cogentus Pharmaceuticals

Alternative Names: CGT-2168

Latest Information Update: 23 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cogentus Pharmaceuticals
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiplatelets; Antiulcers; Gastric antisecretories; Thiophenes
  • Mechanism of Action Platelet activating factor inhibitors; Platelet ADP receptor antagonists; Platelet aggregation inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Ischaemic heart disorders; Peptic ulcer

Most Recent Events

  • 17 Mar 2010 Drug interactions data from two clinical trials released by the European Medicines Agency
  • 03 Sep 2008 Pharmacokinetics data from a phase I trial in healthy volunteers presented at the Congress of the European Society of Cardiology (ESC-2008)
  • 16 Jun 2008 Phase-III clinical trials in Ischaemic heart disorders in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top